{"id":"captopril-tablets","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"0.1-0.5","effect":"Angioedema"},{"rate":"5-10","effect":"Hypotension"},{"rate":"2-5","effect":"Taste disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Captopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By reducing angiotensin II levels, the drug causes vasodilation, decreases peripheral vascular resistance, and reduces aldosterone secretion, leading to lower blood pressure and reduced cardiac workload. This mechanism also provides cardioprotective and renoprotective effects.","oneSentence":"Captopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:25.004Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Post-myocardial infarction left ventricular dysfunction"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT05442463","phase":"","title":"Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2020-11-30","conditions":"Hormone Therapy","enrollment":200},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT06485661","phase":"EARLY_PHASE1","title":"Effect of Captopril on GLS in Duchenne Myodystrophy","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-01-01","conditions":"Effect of Drug","enrollment":20},{"nctId":"NCT06417320","phase":"PHASE4","title":"Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2023-06-01","conditions":"Nephrotic Syndrome in Children","enrollment":60},{"nctId":"NCT06253429","phase":"PHASE3","title":"Alpha-lipoic Acid in Diabetic Nephropathy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-01-01","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT04835233","phase":"PHASE4","title":"Management of Hypertension in the Early Postpartum: a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Federal University of Paraíba","startDate":"2021-05-01","conditions":"Pregnancy-Induced Hypertension in Postpartum, Postpartum Pre-Eclampsia, Hypertension","enrollment":180},{"nctId":"NCT06141200","phase":"PHASE3","title":"NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial","status":"UNKNOWN","sponsor":"Natural Wellness Egypt","startDate":"2024-03","conditions":"Essential Hypertension","enrollment":286},{"nctId":"NCT06039592","phase":"","title":"Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":164},{"nctId":"NCT06039540","phase":"","title":"Study of Drug Therapy for Pediatric Heart Failure","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-01-01","conditions":"Heart Failure Congenital","enrollment":200},{"nctId":"NCT06037434","phase":"","title":"Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":122},{"nctId":"NCT04878315","phase":"PHASE1","title":"Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2022-02-13","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT04964050","phase":"PHASE1","title":"A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2022-04-21","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT04755946","phase":"PHASE3","title":"Possible Role of Roflumilast in Diabetic Nephropathy","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2021-03-10","conditions":"Diabetic Nephropathies","enrollment":48},{"nctId":"NCT04485845","phase":"PHASE4","title":"Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-11-01","conditions":"Metabolic Syndrome, Diabete Type 2, Kidney Insufficiency","enrollment":39},{"nctId":"NCT01271478","phase":"PHASE4","title":"Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2009-08","conditions":"Inflammation, End-stage Renal Disease","enrollment":60},{"nctId":"NCT01292694","phase":"PHASE1","title":"Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2011-03","conditions":"Hypertension, Pure Autonomic Failure, Multiple System Atrophy","enrollment":12},{"nctId":"NCT03147092","phase":"EARLY_PHASE1","title":"Matão Controlling Hypertension (MatCH Study): Rationale and Design","status":"UNKNOWN","sponsor":"Centro Neurológico de Pesquisa e Reabiitação, Brazil","startDate":"2018-02-01","conditions":"Hypertension, Blood Pressure","enrollment":15000},{"nctId":"NCT02217852","phase":"PHASE4","title":"Treatment of Hypertension in Tibetan Adult Population","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2014-08","conditions":"Hypertension","enrollment":800},{"nctId":"NCT00660309","phase":"PHASE4","title":"A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":45},{"nctId":"NCT00663949","phase":"PHASE2, PHASE3","title":"Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2006-02","conditions":"Diabetic Nephropathy","enrollment":70}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"ELECTROLYTE IMBALANCE"},{"count":2,"reaction":"WEIGHT DECREASED"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ANGIOEDEMA"},{"count":1,"reaction":"ANURIA"},{"count":1,"reaction":"BLOOD PRESSURE DECREASED"},{"count":1,"reaction":"CARDIAC FAILURE ACUTE"},{"count":1,"reaction":"CARDIOMEGALY"},{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"}],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Capoten"],"phase":"marketed","status":"active","brandName":"Captopril Tablets","genericName":"Captopril Tablets","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Captopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure. Used for Hypertension, Heart failure, Post-myocardial infarction left ventricular dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}